Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 5/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.40 |
| ▸ | RECQL | P46063 | 1/20 | 0.40 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | NPSR1 | Q6W5P4 | 4/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.37 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.37 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6489028 | 0.87 | L3MBTL1 (0.47) | L3MBTL1MEN1KMT2ACYP1A2CYP2C19 | |
| SCHEMBL6488038 | 0.82 | KMT2A (0.47) | L3MBTL1MEN1KMT2ACYP1A2CYP2C19 | |
| SCHEMBL7068552 | 0.81 | KMT2A (0.43) | L3MBTL1MEN1KMT2ACYP1A2CYP2C19 | |
| SCHEMBL6487724 | 0.80 | HDAC1 (0.39) | MEN1KMT2ACYP1A2CYP3A4HPGD | |
| SCHEMBL6492219 | 0.78 | DRD2 (0.36) | RECQLNPSR1SMN1; SMN2MAPK1 | |
| SCHEMBL7068553 | 0.76 | MEN1 (0.45) | L3MBTL1MEN1KMT2ACYP1A2CYP2C19 | |
| SCHEMBL7135143 | 0.75 | SMN1; SMN2 (0.48) | MEN1KMT2ACYP1A2CYP2C19CYP3A4 | |
| SCHEMBL6502820 | 0.74 | ALOX5AP (0.42) | L3MBTL1MEN1KMT2AHPGDALDH1A1 | |
| SCHEMBL6496800 | 0.73 | TDP1 (0.38) | L3MBTL1MEN1KMT2ACYP1A2CYP2C19 | |
| SCHEMBL21991924 | 0.70 | PPARA (0.53) | ALDH1A1NPSR1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050014812-A1 | Benzimidazole compounds | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2005-01-20 | — | — | US | disclosed |
| WO-2004108686-A2 | BENZIMIDAZOLE COMPOUNDS HAVING HYPOGLYCEMIC ACTIVITY | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2004-12-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050014812-A1 | Benzimidazole compounds | SLC5A1, SLC5A2, G6PD | L3MBTL1 790/4885MEN1 1604/4885KMT2A 561/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.